News & Perspective

Oct 25, 2001

Oct 25, 2001

Studies raise hopes for invention of drugs to block anthrax toxin

Oct 25 (CIDRAP News) – Two studies published online by Nature this week help explain how anthrax toxin works, possibly paving the way for the development of drugs that could block the toxin's action. One group of researchers explains how it identified the cell-surface receptor that enables anthrax toxin to invade host cells, while another group describes the precise molecular structure of a key component of the toxin.

Nov 30, 2001

Nov 30, 2001

Acambis wins new contract to supply 155 million doses of smallpox vaccine

Nov 29, 2001 (CIDRAP News) – The US Department of Health and Human Services (HHS) has awarded Acambis Inc. a $428 million contract to produce an additional 155 million doses of smallpox vaccine by the end of 2002, HHS Secretary Tommy G. Thompson announced Wednesday.

Nov 14, 2002

Nov 14, 2002

HHS to study whether chronic wasting disease threatens humans

Editor's note: This story was updated Nov 15 to include additional information from Food and Drug Administration officials.

(CIDRAP News) – Federal health officials have announced plans to expand research on whether chronic wasting disease (CWD) in deer and elk poses a threat to humans and other species.

Aug 07, 2003

Aug 07, 2003

Ebola--improved outbreak containment may be near at hand

(CIDRAP News) – Researchers from the National Institute of Allergy and Infectious Diseases (NIAID) have determined that a single injection of a fast-acting experimental Ebola vaccine confers protection against the disease in monkeys after just 1 month.

Oct 01, 2003

Oct 01, 2003

NIAID funds 11 new biodefense labs

(CIDRAP News) – Federal health officials yesterday announced grants to build 11 new biodefense laboratories around the country, including two that will be authorized to study the most dangerous pathogens.

Nov 07, 2003

Nov 07, 2003

Acambis launches clinical trial of West Nile vaccine

(CIDRAP News) – The British biotechnology company Acambis announced yesterday that it has launched the first clinical trial of its vaccine for West Nile virus, called ChimeriVax-West Nile.

The phase 1 trial will involve 60 adult volunteers in Lenexa, Kan., the company said in a news release. The volunteers will receive one of three doses of the West Nile vaccine or a licensed yellow fever vaccine that is being used as a control.

Dec 09, 2003

Dec 09, 2003

NIAID funds tularemia research at New York school

(CIDRAP News) – Albany Medical College in Albany, N.Y., has received an $8.3 million federal grant to study pulmonary tularemia, with the main emphasis on developing a vaccine, college officials announced last week.

The grant from the National Institute of Allergy and Infectious Diseases (NIAID) will fund tularemia research at the college for 4½ years, the college said in a news release.

Jul 16, 2004

Jul 16, 2004

NIAID expands trial of West Nile treatment

Rev

Sep 10, 2004

Sep 10, 2004

1950s smallpox vaccine passes dilution test

(CIDRAP News) – A test of smallpox vaccine made by Aventis Pasteur in the 1950s show it is still effective even when diluted, suggesting that the United States has more than enough vaccine for everyone, according to a report this week in the Journal of the American Medical Association.

Sep 21, 2004

Sep 21, 2004

HHS awards contract for H5N1 avian flu vaccine

(CIDRAP News) – In a bid to limit the threat of an influenza pandemic, the Department of Health and Human Services (HHS) is awarding a contract to Aventis Pasteur Inc. to make 2 million doses of a vaccine for humans to protect against H5N1 avian influenza.

Pages

by Topic

by country

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3MAccelerate DiagnosticsGilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»